BGIG ETF Volume Surges 11x as Johnson & Johnson Shines

Bahl & Gaynor Income Growth ETF (BGIG) has seen unusual trading volume, which is 11× higher than its average daily volume.

The ETF’s largest holding, Johnson & Johnson, drew fresh analyst attention as J.P. Morgan reiterated a Hold rating and price target, while the broader Street maintains a Moderate Buy view with modest upside, keeping the healthcare giant in focus for income investors. Broadcom, another key position, was hit by a downgrade to Hold on concerns over slower software growth even as it guides for robust revenue and AI chip sales, and it also announced a planned CFO transition in 2026 aimed at supporting its long-term strategy. Microsoft, a top tech holding, continues to dominate ETF narratives as it reports strong early monetization of its Copilot AI tools, unveils a $10 billion AI and cybersecurity investment plan in Japan, and warns about new security risks like “AI recommendation poisoning,” all while analysts remain broadly bullish despite the stock’s year-to-date pullback. Eli Lilly and AbbVie both reported progress on clinical studies—Lilly with completion of an early-stage safety trial for experimental drug LY4060874, and AbbVie with a real-world migraine study of Ubrelvy and Qulipta—updates that could influence long-term growth expectations for these core pharma names. Taiwan Semiconductor Manufacturing has also been in the spotlight after a sharp share-price rise driven by optimism around booming AI chip demand and bullish analyst commentary ahead of its upcoming earnings report, underscoring the ETF’s exposure to the AI hardware supply chain.